Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGOG OV5: Surgery and Niraparib in Recurrent Ovarian Cancer
NCT03983226Phase 2Recruiting
- Sponsor
- Shanghai Gynecologic Oncology Group
- Start
- Oct 2019
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of niraparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by Shanghai Gynecologic Oncology Group. Started Oct 2019; status: recruiting.
02
Drugs
niraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03983226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03983226.